Journal
BLOOD
Volume 104, Issue 3, Pages 655-658Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2003-07-2345
Keywords
-
Categories
Ask authors/readers for more resources
Alemtuzumab is a monoclonal antibody to CD52 that has activity in T-cell leukemia and lymphoma. This study alms to describe the complications and outcomes of a subset of patients with mycosis fungoides/Sezary syndrome who were treated with alemtuzumab. Four of 8 patients, with no prior history of cardiac problems, developed significant cardiac toxicity (congestive heart failure or arrhythmia) that mostly improved after alemtuzumab discontinuation. The role of this agent in potentially inducing important cardiac side effects is suggested and argues for further investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available